MedTrace Logo

Drug-induced Repolarization ECG Changes

NCT03642405 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2019-01-03

No results posted yet for this study

Summary

Studies have shown that the risk of developing heart arrhythmias, is increased in patients receiving medication for Attention-deficit hyperactivity disorder (ADHD) and depression. The QT-interval on a electrocardiogram (ECG) is often used to assess the patients risk of developing heart arrhythmias. The QT-interval defines the hearts electrical resting period and a long interval is linked to an increased risk of developing heart arrhythmias. In this project the investigators wish to examine possible side-effects in patients receiving medication for ADHD and depression and their dynamic QT-interval changes, by analysing the ECG changes that occur during "Brisk Standing".

Conditions

  • Long QT Syndrome
  • ADHD
  • Depression
  • Death
  • Death, Sudden, Cardiac
  • Romano-Ward Syndrome
  • Pathologic Processes
  • Heart Arrest
  • Electrocardiogram: Electrical Alternans
  • Heart Diseases
  • Cardiovascular Diseases
  • Death, Sudden
  • Arrhythmias, Cardiac
  • Heart Defects, Congenital
  • Cardiovascular Abnormalities
  • Congenital Abnormalities
  • Genetic Disease
  • Genetic Syndrome
  • Qt Interval, Variation in
  • Psychiatric Disorder

Interventions

DIAGNOSTIC_TEST

Electrocardiogram examination

12-lead ECG monitored by Holter

DIAGNOSTIC_TEST

Echocardiography

Echocardiography in accordance to Danish Society of Cardiology

PROCEDURE

Blood Samples

Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).

BEHAVIORAL

Questionnaire

Questionnaire regarding patients quality of life

Sponsors & Collaborators

  • Copenhagen University Hospital at Herlev

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-15
Primary Completion
2019-09-03
Completion
2022-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03642405 on ClinicalTrials.gov